Vaginal lactoferrin in asymptomatic patients at low risk for pre-term labour for shortened cervix: cervical length and interleukin-6 changes

J Obstet Gynaecol. 2013 Feb;33(2):144-8. doi: 10.3109/01443615.2012.740527.

Abstract

A total of 3,324 singleton pregnant women were screened for pre-term delivery and 128 women were finally randomised and analysed for outcome showing borderline cervical length (25-29 mm) and elevated cervico-vaginal interleukin 6 levels. To verify if vaginal administration of lactoferrin might have an influence on these variables, two groups of 64 patients were formed. Study cases were submitted to lactoferrin for 21 days; controls received no treatment. An inverse relation was found between interleukin 6 levels and cervical length. On day 30 from the beginning of the treatment, study cases showed a decrease in interleukin 6 levels and an increase in cervical length. A greater number of women with regular uterine contractions and reduced cervical consistency before the 37th week of gestation were found in the controls. Our data show that lactoferrin could play a role in reducing the number of women at risk for pre-term birth for shortened cervical length and elevated interleukin 6 levels.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravaginal
  • Animals
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Biomarkers / metabolism
  • Cattle
  • Cervical Length Measurement*
  • Cervix Uteri / drug effects*
  • Cervix Uteri / metabolism
  • Female
  • Interleukin-6 / metabolism*
  • Lactoferrin / pharmacology
  • Lactoferrin / therapeutic use*
  • Longitudinal Studies
  • Obstetric Labor, Premature / prevention & control*
  • Pregnancy
  • Prospective Studies
  • Vaginal Smears

Substances

  • Anti-Infective Agents
  • Biomarkers
  • Interleukin-6
  • Lactoferrin